Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tazemetostat · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| tazemetostat | DRUG | Dose Escalation Phase (Phase IIa): Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days; Dose Expansion Phase (Phase IIb): Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days |
| HMPL-689 | DRUG | Dose Escalation Phase (Phase IIa): HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days. Dose Expansion Phase (Phase IIb): HMPL-689 (RP2D) in a therapeutic cycle of 28 days |
Tazemetostat is used for the treatment of relapsed/refractory follicular lymphoma with EZH2 and relapsed/refractory lymphoma. It is a small molecule oncology drug being developed by HUTCHMED (China) Limited (HCM). It has received FDA priority review and accelerated approval designations.
Tazemetostat targets EZH2, as indicated by its use in relapsed/refractory follicular lymphoma with EZH2. It is a small molecule designed to address this specific molecular target in oncology.
Tazemetostat is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is conducting clinical trials for this drug in oncology indications.
Tazemetostat is in Phase 2 clinical development. It is an investigational drug and has not been approved for general use. The FDA has granted it priority review and accelerated approval designations, but it remains in clinical trials.
Tazemetostat has been studied in two completed Phase 2 trials. NCT05467943 enrolled 42 patients with relapsed/refractory follicular lymphoma with EZH2. NCT05713110 enrolled 61 patients with relapsed/refractory lymphoma, testing tazemetostat in combination with HMPL-689.
No, Tazemetostat is not the same as HMPL-689. In one clinical trial, NCT05713110, tazemetostat was studied in combination with HMPL-689 in patients with relapsed/refractory lymphoma. They are separate drugs used together in that study.